Given that ACBD3 has previously been reported to be upregulated in breast cancer and that our bioinformatic data supported this, coupled with our survival analyses supporting previous findings [22], we do not believe that genetic heterogeneity of different cohorts can explain these differences. The gene discussed is ACBD3; the disease is breast carcinoma.